Merck Sharp + Dohme Corp.

Schering Corporation

Haiqun Tang

Jing Su

Zhiqiang Zhao

Li Xiao

Shuzhi Dong

Dexi Yang

Alexander Pasternak

Jinlong Jiang

Xin Gu

Brian Alexander McKittrick

Jack D Scott

Wen-Lian Wu

Yuhua Huang

Katherine Young

Anandan Palani

John W Clader

Frank W Bennett

Guoqing Li

Jianmin Fu

Ashwin Umesh Rao

Thavalakulamgara K Sasikumar

Ruo Xu

Zhibo Zhang

Li Qiang

Mark D McBriar

Jared N Cumming

William K Hagmann

Duane A Burnett

Robert G Aslanian

Hubert B Josien

Xianhai Huang

Dong Xiao

Fa-Xiang Ding

Haifeng Tang

Hong Liu

Shawn P Walsh

Dmitri A Pissarnitski

Derun Li

Alan W Hruza

Hongmei Li

Theodros Asberom

John P Caldwell

Brandon Mitsuo Taoka

Weidong Pan

Kevin D Dykstra

Chad E Bennett

Jun Qin

Thomas A Bara

Mihir Mandal

Martin Domalski

Chad E Knutson

Mary Ann Caplen

Shu-Wei Yang

Andreas Verras

Murali Rajagopalan

David James Cole

Reynalda DeJesus

David N Hunter

Xu Zhang

Kevin D McCormick

Hongjun Zhang

Ying Huang

Younong Yu

Phieng Siliphaivanh

Joey Lee Methot

Christopher W Boyce

Purakkattle J Biju

Robert D Mazzola, Jr

Xiao Chen

Clare London

Jayaram R Tagat

Wei Zhou

Qin Jiang

Jacqueline D Hicks

Jianping Pan

Elizabeth Helen Kelley

Li Dong

Rachel Nicola MacCoss

Rui Zhang

Claire Lankin

Ning Shao

Hong Dong Chu

Pawan Dhondi

Yunfeng Bai

Zhixiang Zheng

Matthew Lombardo

Sylvia Joanna Degrado

Dipshikha Biswas

W Michael Seganish

Jolicia Polivina Gauuan

Andrew J Leyhane

Jennifer Hanisak

Mary Anne Caplen

Brandon M Taoka

Kevin D Mccormick

Amy McCracken

Tianyuan Zhang

Alex Pasternak

Ying R Huang

Frank Bennett

The present invention relates to metallo-&#x3b2;-lactamase inhibitor compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein Z, R, X, Xand Rare as defined herein. The present invention also relates to compositions which comprise a metallo-&#x3b2;-lactamase inhibitor compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, optionally in combination with a beta lactam antibiotic and/or a beta-lactamase inhibitor. The invention further relates to methods for treating a bacterial infection comprising administering to a patient a therapeutically effective amount of a compound of the invention, in combination with a therapeutically effective amount of one or more &#x3b2;-lactam antibiotics and optionally in combination with one or more beta-lactamase inhibitor compounds. The compounds of the invention are useful in the methods described herein for overcoming antibiotic resistance. 

Metallo-beta-lactamase inhibitors and methods of use thereof

The present invention relates to metallo-&#x3b2;-lactamase inhibitor compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein Z, R, X, Xand Rare as defined herein. The present invention also relates to compositions which comprise a metallo-&#x3b2;-lactamase inhibitor compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, optionally in combination with a beta lactam antibiotic and/or a beta-lactamase inhibitor. The invention further relates to methods for treating a bacterial infection comprising administering to a patient a therapeutically effective amount of a compound of the invention, in combination with a therapeutically effective amount of one or more &#x3b2;-lactam antibiotics and optionally in combination with one or more beta-lactamase inhibitor compounds. The compounds of the invention are useful in the methods described herein for overcoming antibiotic resistance.

Metallo-beta-lactamase inhibitors

Described herein are compounds of Formula (I) or a pharmaceutically acceptable salt thereof. The compounds of Formula I act as Cyp8b1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for diabetes and cardiovascular disease. 

Compound useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolc disease

Described herein are compounds of Formula I or a pharmaceutically acceptable salt thereof. The compounds of Formula I act as Cyp8b1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for diabetes and cardiovascular disease.

Compounds useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolic disease

The present invention relates to metallo-&#x3b2;-lactamase inhibitor compounds of Formula I: (I) and pharmaceutically acceptable salts thereof, wherein Z, R, X, Xand Rare as defined herein. The present invention also relates to compositions which comprise a metallo-&#x3b2;-lactamase inhibitor compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, optionally in combination with a beta lactam antibiotic and/or a beta-lactamase inhibitor. The invention further relates to methods for treating a bacterial infection comprising administering to a patient a therapeutically effective amount of a compound of the invention, in combination with a therapeutically effective amount of one or more &#x3b2;-lactam antibiotics and optionally in combination with one or more beta-lactamase inhibitor compounds. The compounds of the invention are useful in the methods described herein for overcoming antibiotic resistance. 

Metallo-&#x3b2;-lactamase inhibitors

The present invention relates to metallo-beta-lactamase inhibitor compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein Z, R, X, Xand Rare as defined herein. The present invention also relates to compositions which comprise a metallo-beta-lactamase inhibitor compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, optionally in combination with a beta-lactam antibiotic and/or a beta-lactamase inhibitor. The invention further relates to methods for treating a bacterial infection comprising administering to a patient a therapeutically effective amount of a compound of the invention, in combination with a therapeutically effective amount of one or more &#x3b2;-lactam antibiotics and optionally in combination with one or more beta-lactamase inhibitor compounds. The compounds of the invention are useful in the methods described herein for overcoming antibiotic resistance. 

The present invention relates to compounds of formula I that are metallo-&#x3b2;-lactamase inhibitors, the synthesis of such compounds, and the use of such compounds for use with &#x3b2;-lactam antibiotics for overcoming resistance. 

Beta-tetrazolyl-propionic acids as metallo-beta-lactamase inhibitors

The present invention relates to compounds of formula (I) that are metallo-&#x3b2;-lactamase inhibitors, the synthesis of such compounds, and the use of such compounds for use with &#x3b2;-lactam antibiotics for overcoming resistance. 

The present invention relates to inhibitors of IRAK4 of Formula (I) and provides compositions comprising such inhibitors, as well as methods therewith for treating IRAK4-mediated or -associated conditions or diseases.

Inhibitors of IRAK4 activity

This application provides for compounds of the formula Formula I or a pharmaceutically acceptable salt thereof, wherein the individual variables are defined herein, as well as processes to prepare these compounds, pharmaceutical compositions comprising the same and their use in treating disease state associated with the CRTHreceptor. 

[object Object]

This invention discloses novel gamma secretase inhibitors of the formula: Rand R, or Rand R, or Rand R, together with the atoms to which they are bound, can form a fused cycloalkyl or fused heterocycloalkyl ring. The cycloalkyl ring or the heterocycloalkyl ring can be optionally substituted with one or more substituents. One or more compounds of formula (I), or formulations comprising such compounds, may be useful, e.g. in treating Alzheimer's Disease.

Benzenesulfonyl-chromane, thiochromane, tetrahydronaphthalene and related gamma secretase inhibitors

This invention discloses novel gamma secretase inhibitors of the formula: Rand R, or Rand R, or Rand R, together with the atoms to which they are bound, can form a fused cycloalkyl or fused heterocycloalkyl ring. The cycloalkyl ring or the heterocycloalkyl ring can be optionally substituted with one or more substitutents. One or more compounds of formula (I), or formulations comprising such compounds, may be useful, e.g. in treating Alzheimer's Disease.

A compound having the general structure of Formula (I): or a pharmaceutically acceptable salt, solvate, ester, or tautomer thereof, and or a pharmaceutically acceptable salt, solvate, ester, or tautomer thereof, are useful in treating diseases, disorders, or conditions such as metabolic syndrome and dyslipidemia.

Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia

The present invention discloses compounds of formula I wherein m, n, p, R, Rand X, are herein defined, the compounds being novel antagonists for melanin-concentrating hormone (MCH), as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such MCH antagonists as well as methods of using them to treat obesity, metabolic disorders, eating disorders such as hyperphagia, and diabetes.

Heterocyclyls as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders

The present invention discloses compounds which, are novel antagonists for melanin-concentrating hormone (MCH), as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such MCH antagonists as well as methods of using them to treat obesity, metabolic disorders, eating disorders such as hyperphagia, and diabetes.

MCH antagonists for the treatment of obesity

Growing community of inventors

Belle Mead, NJ, United States of America

Haiqun Tang